Description
Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC₅₀'s of 2.7 and 4.5 nM for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis.
Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC₅₀'s of 2.7 and 4.5 nM for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis.
2139 | Ruxolitinib, Free base DataSheet
Alternate Name/Synonyms: INCB018424; INC18424; NCB018424; NCB18424
Appearance: Off-white solid
Formulation: N/A
CAS Number: 941678-49-5
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₁₇H₁₈N₆
Molecular Weight: 306.37
Cell-Permeable?: Yes
Purity: ≥99% by HPLC
Solubilities: DMSO (25 mg/ml) or EtOH (~ 15 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent JAK inhibitor
MDL Number: MFCD12031592
PubChem CID: 25126798
SMILES: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChi: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChi Key: HFNKQEVNSGCOJV-OAHLLOKOSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
24months |